GLP-1 Evidence

Airteagal

An gcosnaíonn GLP-1 na duáin? Cad a thomhais na trialacha

Updated 4 min read 37 citations

Binse ceimiceachta anailíseach feistithe le gloine do thitríocht agus tomhas pH
Jean-Pierre from Cosne-Cours-sur-Loire (Nièvre, Burgundy… · CC BY-SA 2.0 · Wikimedia Commons

Déan cuardach ar "ozempic kidney disease" nó "semaglutide chronic kidney disease" agus aimseoidh tú go leor éileamh dearfach agus an-bheagán nasc chuig fíorthriail. An leagan gairid: is ceann de na torthaí neamh-mheáchain is fearr tacaithe don aicme dhrugaí seo é an comhartha duán, ach ciallaíonn "cosaint na nduán" rud níos cúinge agus níos sainiúla ná mar a thugann formhór an chlúdaigh le tuiscint — ráta laghdaithe moillithe i bhfeidhm na nduán agus níos lú teagmhas cliseadh duán i dtrialacha, ní cóireáil do ghalar duán i gcoitinne.

Cad is brí le "torthaí duán" sna trialacha seo

Ní fhiafraíonn trialacha sa réimse seo an "gcabhraíonn" druga "leis na duáin." Rianaíonn siad comhshraith shainithe: titim leanúnach sa ráta scagtha glomarúil measta (eGFR), dul chun cinn go cliseadh duán, gá le hidildiailis nó le trasphlandú, nó bás de bharr cúiseanna duáin nó cardashoithíocha. Scrúdaigh athbhreithniú córasach agus meitea-anailís 2025 ar thrialacha randamaithe in othair a raibh galar duán ainsealach acu cheana agonaigh ghabhdóir GLP-1 i gcoinne comhshraithe den chineál seo agus thuairiscigh siad tairbhe chomhsheasmhach [4]. Tháinig meitea-anailís neamhspleách eile, ó 2025 freisin, ar thrialacha rialaithe randamaithe ar an gconclúid chéanna agus í ag féachaint ar thorthaí duán agus cardashoithíocha le chéile [2].

Ní toradh úrnua é seo atá gléasta suas do 2025. Bhí anailísí comhthiomsaithe níos luaithe ar thrialacha torthaí cardashoithíocha tar éis comhartha duán a aimsiú cheana féin ag taisteal in éineacht leis an gceann cardashoithíoch, ag dul siar go dtí athbhreithniú córasach agus meitea-anailís 2019 ar thrialacha torthaí cardashoithíocha i ndiaibéiteas cineál 2 [8] agus deimhnithe arís i nuashonrú 2021 ag baint úsáide as an gcur chuige céanna [19]. Tá an toradh duán athdhéanta trasna roinnt cleachtaí comhthiomsaithe neamhspleácha seachas a bheith ag brath ar aon triail cheannlíne amháin — rud atá ina bhonn fianaise atá difriúil go suntasach ó staidéar dearfach amháin.

Sonraí duán tirzepatide féin

Tá fianaise thiomnaithe féin ag an agonaí déach GIP/GLP-1. Rinne anailís iar-hoc ar thriail SURPASS-4 comparáid idir tirzepatide agus insulin glargine ar thorthaí duán i ndaoine a bhfuil diaibéiteas cineál 2 orthu agus fuarthas tairbhe do tirzepatide ar an bpointe deiridh duánach comhshraithe [12]. Comparáid í sin le cóireáil ghníomhach a bhfuil glúcós-ísliú aitheanta aici, ní le placebo, rud a neartaíonn an cás nach bhfuil an éifeacht ach "go gcabhraíonn aon rialú glúcóis beagán leis na duáin."

Cén fáth a bhfuil difear idir éifeacht mheáchan-idirghabhálach agus éifeacht dhíreach tábhachtach anseo

Tá an gaol idir otracht agus na duáin bunaithe go maith sa litríocht cheana féin: is tiománaí neamhspleách é meáchan iomarcach ar dhul chun cinn galar duán trí roinnt meicníochtaí, lena n-áirítear hipearscagadh glomarúil [17]. Cruthaíonn sé sin an fhadhb léirmhínithe chéanna a ardaíonn an suíomh seo ar an leathanach torthaí cardashoithíocha: bheifí ag súil go gcabhródh druga a tháirgeann caillteanas meáchain mór, marthanach leis na duáin go pointe áirithe beag beann ar aon éifeacht dhíreach ó ghabhdóir GLP-1 ar fhíochán duánach. Ní féidir leis na trialacha, mar atá siad deartha, "tháinig feabhas ar na duáin toisc go bhfuil an duine níos éadroime agus go bhfuil brú fola agus rialú glúcóis níos fearr aige" a scaradh go glan ó "tá meicníocht chosanta dhíreach ag gníomhachtú ghabhdóir GLP-1 sa duán." Tá an dá cheann inchreidte; níl seasamh ag sonraí na trialach le ceachtar acu, agus ní gá an cheist sin a réiteach chun go mbeadh an toradh úsáideach go cliniciúil.

An fhianaise a léamh ar an toirt

CeistAn méid a léiríonn na sonraíMuinín
An gcuireann an aicme dhrugaí moill ar mheath fheidhm na nduán i ndaoine a bhfuil CKD orthu cheana?Tá, trasna dhá mheitea-anailís neamhspleácha 2025 de RCTanna ar a laghadSách láidir
An bhfuil an éifeacht sonrach do dhruga amháin, nó ar fud na haicme ar fad?Clúdaíonn an fhianaise móilíní iolracha GLP-1 agus déach-agonaí, lena n-áirítear comparáid stíl aghaidh-ar-aghaidh do tirzepatideMeasartha — is i measc daonraí diaibéiteacha atá an chuid is mó den doimhneacht
An éifeacht dhíreach ar na duáin í, nó éifeacht iartheachtach ó rialú meáchain agus glúcóis?Gan réiteach; tá an dá mheicníocht inchreidte go bitheolaíochCeist oscailte
An gciallaíonn sé seo go gcóireálann an druga galar duán as féin?Níl — is fianaise chúntach í laistigh de chúram diaibéiteas agus otracht, ní táscaire galar duán sa chiall a bheadh ag druga a bheadh sainiúil don néifreolaíochtNá déan áibhéil

An méid nach n-insíonn sé seo duit

Níor liostáil aon cheann de na trialacha seo daoine go sonrach mar go raibh galar duán acu agus gan diaibéiteas ná otracht orthu — is cóhóirt diaibéiteacha iad na daonraí agus, sna hathbhreithnithe is nuaí, cóhóirt CKD mheasctha atá ar theiripe chosanta duán eile cheana féin. Tá sé sin tábhachtach d'aon duine a léann an ceannlíne "laghdaíonn drugaí GLP-1 an riosca cliseadh duán" agus atá ag smaoineamh an mbaineann sé leo féin go sonrach. Ní insíonn sé duit ach an oiread faoi choigeartuithe dáileoige atá ag teastáil i lagú duán chun cinn, rud atá ina cheist chógas-chinéiticiúil nár deartha na trialacha luaite lena freagairt.

Ceisteanna coitianta

An gciallaíonn sé seo gur féidir le semaglutide nó tirzepatide ionadú a dhéanamh ar inhibiteoir ACE nó inhibiteoir SGLT2 chun na duáin a chosaint?
Níor thástáil aon triail an t-ionadú sin. Tá an tairbhe duán le feiceáil i measc daonraí a bhí, den chuid is mó, ag fáil cóir chaighdeánach duán agus cardashoithíoch cheana féin. Is fianaise í seo ar thairbhe bhreise, ní ar ionadú.
An bhfuil an tairbhe duán níos mó i ndaoine a bhfuil galar duán níos forbartha acu?
Fuair an t-athbhreithniú 2025 a bhí sonrach do CKD tairbhe laistigh de dhaonra a raibh galar duán ainsealach acu cheana féin, rud atá ina fhreagra níos dírí ná mar a thiocfadh ó na hanailísí cóhóirt diaibéiteas níos luaithe, ach ní rud é éifeachtaí fo-ghrúpa de réir chéim CKD ar féidir le hachoimre ghairid freagairt dó go hiontaofa — tá an sonra sin le fáil laistigh den athbhreithniú iomlán.
An ndéanann caillteanas meáchain amháin, gan druga GLP-1, an rud céanna do na duáin?
D'fhéadfadh sé, go réasúnta, méid inchomparáide a bheith ann don chuid mheáchan-idirghabhálach den éifeacht, ach níl aon triail aghaidh-ar-aghaidh ann a dhéanann comparáid idir caillteanas meáchain coibhéiseach a bhaintear amach trí aiste bia agus na drugaí seo ar phointí deiridh sonracha duánach.
Ar cheart do dhuine a bhfuil galar duán acu fiafraí faoi na drugaí seo?
Is comhrá é sin le néifreolaí nó leis an lia atá ag bainistiú cúram duán agus diaibéiteas le chéile, ní cinneadh atá le déanamh ó alt achoimre. Tá an t-alt seo chun críocha eolais amháin agus ní comhairle leighis é; labhair le cliniceoir faoi do chás féin.
Buidéil cheimiceacha lipéadaithe ag seasamh le chéile ar bhinse saotharlainne
564dude · CC BY-SA 3.0 · Wikimedia Commons
An cruthúnas atá taobh thiar den leathanach seo Bar dhíreach a thaispeánann comhoibriú na 19 foilsitheachta a luaitear ar an leathanach seo de réir cineál staidéir. 9712meta-analysis (9)randomised trial (7)review (1)other (2)
19 foils, 2018–2025. Is é sin meascán le trialacha agus sintéis ann, atá mar an suíomh óna bhfuil éileamh faoi chúis réasúnta. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis Peng TR, Lin HH, Tseng TL, et al. · British journal of clinical pharmacology · 2026 · Meta-analysis DOIPubMed 42273973Full text
  2. Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis AbdelMagid AM, Kamel AM, Farid SF · Pharmacotherapy · 2026 · Meta-analysis DOIPubMed 41947610
  3. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  4. Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis Alper A, Fagin A, Karthikeyan A, et al. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026 · Meta-analysis DOIPubMed 42458197
  5. The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis Chuang SM, Liu SC, Chien KL, et al. · Diabetes, obesity & metabolism · 2026 · Meta-analysis DOIPubMed 42219271Full text
  6. Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis Shokravi A, Seth J, Mancini GBJ · Cardiovascular diabetology · 2026 · Meta-analysis DOIPubMed 41761267Full text
  7. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis Elganyny MKE, Elganyni AKE, Maskji HA, et al. · La Clinica terapeutica · 2026 · Meta-analysis DOIPubMed 42340790
  8. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  9. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  10. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis Cleto AS, Schirlo JM, Beltrame M, et al. · International journal of obesity (2005) · 2025 · Meta-analysis DOIPubMed 39396098
  11. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  12. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis Shokravi A, Seth J, Mancini GBJ · Cardiovascular diabetology · 2025 · Meta-analysis DOIPubMed 41029853Full text
  13. Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs Gao H, Wei Q, Zou A, et al. · Frontiers in endocrinology · 2025 · Meta-analysis DOIPubMed 40556828Full text
  14. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  15. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  16. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis Sattar N, McGuire DK, Pavo I, et al. · Nature medicine · 2022 · Meta-analysis DOIPubMed 35210595Full text
  17. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  18. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  19. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  20. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis Bethel MA, Patel RA, Merrill P, et al. · The lancet. Diabetes & endocrinology · 2018 · Meta-analysis DOIPubMed 29221659
  21. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  22. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight Malhotra A, Grunstein RR, Azarbarzin A, et al. · Sleep medicine · 2025 · Randomised controlled trial DOIPubMed 41135142Full text
  23. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) Agarwal R, Green JB, Heerspink HJL, et al. · Diabetes care · 2025 · Randomised controlled trial DOIPubMed 40968755Full text
  24. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  25. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  26. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  27. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  28. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes] Scheen AJ, Radermecker RP, Paquot N · Revue medicale suisse · 2022 · Randomised controlled trial DOIPubMed 36004653
  29. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  30. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure Marso SP, Baeres FMM, Bain SC, et al. · Journal of the American College of Cardiology · 2020 · Randomised controlled trial DOIPubMed 32164886
  31. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Hartman ML, Sanyal AJ, Loomba R, et al. · Diabetes care · 2020 · Randomised controlled trial DOIPubMed 32291277Full text
  32. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  33. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Van Kleef LA, Michel M, Alkhouri N, et al. · Drug design, development and therapy · 2026 · Review DOIPubMed 41868171Full text
  34. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics Nicholls SJ, Bhatt DL, Buse JB, et al. · American heart journal · 2024 · Clinical trial DOIPubMed 37758044
  35. Chronic Kidney Disease and Obesity Hojs R, Ekart R, Bevc S, et al. · Nephron · 2023 · Review DOIPubMed 37271131
  36. New Drug: Tirzepatide (Mounjaro(™)) Gettman L · The Senior care pharmacist · 2023 · Journal article DOIPubMed 36751934
  37. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original